Results 81 to 90 of about 54,679 (264)

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

New England Journal of Medicine, 2023
BACKGROUND The efficacy and safety of treatment with cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal-cell carcinoma are unknown.
T. Choueiri, T. Powles, L. Albiges, M. Burotto, C. Szczylik, B. Żurawski, E. Yañez Ruiz, M. Maruzzo, A. Suárez Zaizar, L. Fein, F. Schutz, D. Heng, Fong Wang, F. Mataveli, Yu-Lin Chang, M. A. Van Kooten Losio, C. Suarez, R. Motzer   +17 more
semanticscholar   +1 more source

Reprogramming the Immune Landscape of Inflammatory Breast Cancer

Advanced Science, EarlyView.
Inflammatory breast cancer is the most lethal subtype of breast cancer and is characterized by an immunosuppressive tumor microenvironment (TME) driven by a complex network of immune cells and inflammatory cytokines, contributing to its aggressiveness and treatment challenges. Immune checkpoint inhibitors, either alone or in combination, show potential
Verena Martinez‐Rodriguez, Suguru Ogata, Xiaoping Wang, Naoto T. Ueno   +3 more
wiley   +1 more source

Biomarkers on melanoma patient T Cells associated with ipilimumab treatment

Journal of Translational Medicine, 2012
Background Ipilimumab induces long-lasting clinical responses in a minority of patients with metastatic melanoma. To better understand the mechanism(s) of action and to identify novel biomarkers associated with the clinical benefit and toxicity of ...
Wang Wenshi, Yu Daohai, Sarnaik Amod A, Yu Bin, Hall Maclean, Morelli Dawn, Zhang Yonghong, Zhao Xiuhua, Weber Jeffrey S   +8 more
doaj   +1 more source

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

JAMA Oncology, 2020
Key Points Question Does adding ipilimumab to nivolumab improve clinical outcomes for patients with advanced hepatocellular carcinoma previously treated with sorafenib?
T. Yau, Yoon-Koo Kang, Tae-You Kim, A. El-Khoueiry, A. Santoro, B. Sangro, I. Melero, M. Kudo, M. Hou, A. Matilla, F. Tovoli, J. Knox, A. Ruth He, B. El-Rayes, M. Acosta-Rivera, Ho Yeong Lim, J. Neely, Yun Shen, T. Wisniewski, Jeffrey Anderson, Chiun Hsu   +20 more
semanticscholar   +1 more source

Advances in Cancer Immunotherapy for Solid Tumors

Advanced Science, EarlyView.
Cancer immunotherapy for solid tumors is rapidly evolving beyond classical checkpoint blockade toward more precise strategies. Emerging checkpoint targets, bispecific antibodies, antibody–drug conjugate combinations, personalized vaccines, cellular therapies, and engineered cytokines are expanding therapeutic possibilities, while biomarker‐guided ...
Shira Gabizon‐Peretz, Harriet M. Kluger   +1 more
wiley   +1 more source

Essential Updates 2024–2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization

Annals of Gastroenterological Surgery, EarlyView.
This review summarizes key advances from 2024 to 2025 that are reshaping esophageal cancer surgery toward a strategy‐oriented, personalized paradigm through the integration of immunotherapy, population aging, and intelligent technologies. Adjuvant nivolumab after neoadjuvant chemoradiotherapy remains the only perioperative approach with durable benefit,
Shuichiro Oya, Koichi Yagi, Yoshifumi Baba   +2 more
wiley   +1 more source

Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data

Diagnostics, 2018
Recent studies suggest that combining nivolumab with ipilimumab is a more effective treatment for melanoma patients, compared to using ipilimumab or nivolumab alone.
Theodoros G. Soldatos, Antonia Dimitrakopoulou-Strauss, Lionel Larribere, Jessica C. Hassel, Christos Sachpekidis   +4 more
doaj   +1 more source

Prevalence of MSI‐H/dMMR Colorectal Cancer in Japan: Data From the Clinical Study Group of the University of Osaka‐Colorectal Registry

Annals of Gastroenterological Surgery, EarlyView.
Using a multicenter Japanese colorectal cancer cohort from 25 institutions, we analyzed 1464 patients across all disease stages and tumor locations to determine the prevalence and clinicopathological features of MSI‐H/dMMR colorectal cancer. MSI‐H/dMMR tumors accounted for 9.4% of cases overall, were present in 22% of right‐sided colon cancers, and ...
Yoshihiro Morimoto, Mamoru Uemura, Yoshinori Kagawa, Hidekazu Takahashi, Masayuki Hiraki, Yozo Suzuki, Shinichi Yoshioka, Mitsuyoshi Tei, Shu Okamura, Yukako Mokutani, Atsushi Naito, Shinji Tokuyama, Takamichi Komori, Akinobu Yasuyama, Genta Sawada, Yujiro Fujie, Shinya Yamashita, Naotsugu Haraguchi, Yusuke Matsuura, Chu Matsuda, Yoshinao Chinen, Tatsushi Shingai, Katsuki Danno, Nobuo Tanaka, Kazuya Sakata, Kohei Murata, Yuichiro Doki, Hidetoshi Eguchi   +27 more
wiley   +1 more source

Clinical Significance of PD‐L1 and HLA Expression in Esophageal Squamous Cell Carcinoma in Response to Immunotherapy

Annals of Gastroenterological Surgery, EarlyView.
This study evaluated immune‐related biomarkers in esophageal squamous cell carcinoma treated with immune checkpoint inhibitors after postoperative recurrence. PD‐L1 expression in tumor‐associated macrophages and tumor cells, together with HLA class I downregulation and HLA‐DR expression, were associated with favorable responses to immunotherapy.
Kosuke Kanemitsu, Yoshiyuki Tagayasu, Yoshihiro Komohara, Cheng Pan, Rin Yamada, Yukio Fujiwara, Kazuto Harada, Keisuke Kosumi, Yoshifumi Baba, Masaaki Iwatsuki   +9 more
wiley   +1 more source

Humanized immune system animal models and their recent applications

Animal Models and Experimental Medicine, EarlyView.
In this review, we provide an updated and comprehensive overview of the current state of humanized immune system animal model research. We discuss the variety of techniques used to produce humanized mice with their respective strengths and weaknesses, and evaluate the advantages and limitations of these models, including issues with incomplete immune ...
Nicolas Skuli, Rudra B. Amin, A’ishah Bakayoko, Marisa Kruidenier, Sahara Aqui, Sarah J. Skuli, Terence P. Gade   +6 more
wiley   +1 more source